BioCentury
ARTICLE | Company News

Isotechnika, Galenica, ILJIN sales and marketing update

January 9, 2012 8:00 AM UTC

Isotechnika granted Galenica's Vifor Pharma Ltd. specialty pharma business exclusive rights to commercialize voclosporin in the U.S. and territories outside of Canada, China, Hong Kong, Israel, South Africa and Taiwan to treat lupus and proteinuria nephrology indications. Isotechnika will receive an undisclosed upfront payment and is eligible to receive milestones and royalties. Details were not disclosed. ILJIN's ILJIN Life Science Co. Ltd. subsidiary has rights to voclosporin in transplant and autoimmune indications, except lupus, in the U.S. and territories outside of Europe, Canada, Israel, South Africa, China and Taiwan. Isotechnika and the subsidiary reached a deal in which the subsidiary returned rights to voclosporin for lupus but still retains rights to other autoimmune indications. Voclosporin is a transisomer of a cyclosporine analog that inhibits calcineurin (see BioCentury, Nov. 22, 2010).

Paladin Labs Inc. (TSX:PLB, Montreal, Quebec) has rights to develop and commercialize voclosporin from Isotechnika in Latin and Central America, Canada, Israel and South Africa. 3SBio Inc. (NASDAQ:SSRX, Shenyang, China) has rights for transplant and immune indications in China and Taiwan. Isotechnika has rights in Europe to voclosporin. ...